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mitral paravalvular leaks: 
Focus on imaging and technique
paravalvular leaks.(6) This imaging technique will not be dis-
cussed in the present article.
During percutaneous closure, in particular again of mitral leaks, 
3D TOE is mandatory to guide the intervention. It confirms 
adequate crossing of the guidewire through the leak, dem-
onstrates correct and stable positioning of the closure device 
and enables the quantifying of any residual leakage.
In this article, the role of imaging and in particular 3D TOE, 
will be discussed as well as a few suggested closure techniques 
for mitral paravalvular leaks. Furthermore, the technique of 
echo image acquisition will be discussed in detail. An overview 
of current existing data will be provided.
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Paravalvular prosthetic valve leakage is a rare clinical entity. It is 
observed more commonly in the mitral (up to 15%) than the 
aortic (up to 10%) position.(1) Mostly, these leaks are incidental 
findings on transthoracic echocardiography and patients are not 
or hardly symptomatic. Yet, up to 5% of patients will present 
with haemolytic anaemia, heart failure or both. The cause of the 
leakage cannot always be identified, certainly if diagnosed late 
after surgery. Factors that have been identified are tissue fragility 
and calcification, active-subclinical or healed endocarditis and 
suturing technique.(2) If observed early after surgery, the most 
likely cause is technical-surgical while “late” leaks are often a 
consequence of endocarditis. It is therefore of the upmost 
importance to rule out active endocarditis before even con-
sidering percutaneous closure.
Transoesophageal echocardiography (TOE), in particular three-
dimensional (3D) TOE, has emerged as an essential tool in 
the diagnosis and percutaneous management of paravalvular 
leaks.(3-5) If performed properly, it allows direct visualisation of 
the leak, assessment of its size and shape, judgement of the 
distance to the valve annulus and position in relation to the 
leaflets of the valve (in case of a mechanical prosthesis). These 
elements are key to judging feasibility prior to any percutaneous 
closure attempt. Even if angiography may still play a role in the 
assessment of aortic leaks, 3D TOE is the method of choice for 
mitral leaks.
ECG-gated computed tomographic angiography with 3D 
reconstruction is an alternative to 3D TOE in the assessment of 
Symptomatic prosthetic paravalvular leakage is a rare 
clinical condition occurring in up to 5% of patients after 
valve surgery.
Symptoms include haemolytic anaemia, heart failure or 
both. Leaks tend to be more common in the mitral 
compared to the aortic position.
Three dimensional transoesophageal echocardiography 
(3D TOE) is essential prior and during percutaneous 
leak closure. This imaging technique allows to qualify 
and quantify the leak and to judge feasibility of a 
percutaneous approach. It also enables the choice of 
the most appropriated closure device prior to inter-
vention. During the procedure, 3D TOE guides adequate 
crossing of the leak and device deployment. It also fi nally 
allows assessment of the acute procedural result.
Percutaneous closure should be considered as the fi rst 
choice therapy if closure is judged feasible based on 3D 
TOE assessment. This procedure is currently performed 
in a limited number of patients by relatively few 
operators and is characterised by a long learning curve. 
Currently, literature data are scarce and reported acute 
procedural success is roughly around 70 to 80%.
Intervention is mostly performed with vascular plugs or 
ventricular septum defect closure devices. Recently, 
dedicated implants have been made available. Their role 
has been limited to hybrid procedures from a transapical 


















THE ROLE OF IMAGING SCREENING BEFORE 
INTERVENTION
Two dimensional (2D) TOE
At first, the valve prosthesis is scanned by a step-by-step 
rotation of the echo probe, looking for the presence of 
dehiscence and/or paravalvular colour Doppler signals. Occa-
sionally several leaks can be identified. Precise quantification of 
the leak may be difficult in the 2D mode. Only if dehiscence is 
present, can the width of the leak be measured. If colour 
Doppler only unmasks regurgitation, it is advised to measure 
the smallest portion of the jet at the level of the annulus. Both 
measurements will be integrated in the final choice of the 
diameter of the closure device. 2D examination is particularly 
valuable to judge the distance between the paravalvular channel 
and the valve, especially for mechanical prosthesis. Closure 
devices have different characteristics, which will be taken into 
account in order to anticipate leaflet blockage based on these 
measurements. As part of the examination, leaflet motion as 
well as the mean gradient is also recorded.
3D TOE
The crucial role of 3D TOE has been mentioned before. 
Acquisition of the data can be made in a zoom mode to have a 
first appreciation of the defect size and localisation. Then a full 
volume acquisition will provide a high frame rate view of the 
entire valve and annulus. If the defect is visible on the 2D 
images, it will be nicely delineated in a so-called “surgical view” 
of the valve (Figure 1a). Localisation is determined using either 
an anatomical (Figure 1b) or “clock” position (Figure 1c). For 
the anatomical localisation, the annulus of the valve is divided 
into 4 quadrants: septal from the posteromedial aspect of the 
aortic root to the posterior end of the interatrial septum, 
posterior from this point to the middle of the lateral wall of the 
left atrium, lateral from this point to the middle of the left atrial 
appendage and anterior from this point to the middle of the 
posterior aortic root. Using a clock positioning, the annulus is 
divided by an imaginary clock with noon on the aortic root. The 
defect illustrated in figure 1 is a lateral leak at about 8 o’clock. 
When the leak is not visible as a defect in the 2D images, the 
same approach is applied to a 3D colour flow acquisition of the 
mitral valve. To precisely size the leak, both a grey-scale 
acquisition and colour flow data set are used (Figure 2). Using 
dedicated software, a cutting plane parallel to the annulus is 
positioned at the leak level (Figures 2a and 2b) allowing one to 
derive maximal and minimal diameter and area. The shape of 
the leak is also nicely delineated by this approach. Integration of 
the defects’ dimensions, shape and position will determine the 
interventional strategy. The different implants suggested for 




Percutaneous paravalvular leak closure is performed under 
general anaesthesia, ideally in a biplane X-Ray room, and guided 
by 3D TOE. Conceptually, the leak is crossed antegrade from a 
femoral vein-transseptal approach and closed retrograde by 
pulling back a closure device from the left ventricle towards the 
leak up to the base of the left atrium. Exceptionally, a loop has 
to be established by snaring the wire that has crossed the leak 
antegrade. This more complex procedure is only required if 
FIGURE 1:  Topography of mitral paravalvular leaks.
A:  3D echocardiographic view of a large oval-shaped paravalvular leak in a patient with a mitral bioprosthesis.
B:  Localisation according to an anatomical 4 quadrants classification.






8antegrade support is insufficient to cross the leak with the 
“closure-device” delivery catheter and is ideally performed 
from a percutaneous transapical approach in order to provide 
a more co-axial alignment during final closure device deploy-
ment. The guidewire is snared from the transapical sheath and 
externalised to provide the necessary support to cross ante-
grade with the delivery sheath. Snaring from the left ventricle 
after gaining retrograde arterial access through the aortic valve 
is not advised because improper wire-catheter alignment and 
the risk of laceration of the aortic valve. Furthermore, a 
substantial number of patients carry prostheses both in mitral 
and aortic positions, making the latter technique impossible.
It is advised to preventively equip the patient with defibrillation 
pads to treat potential major ventricular arrhythmias during 
wire manipulation in the left ventricle. Once transseptal punc-
ture has been performed successfully, unfractionated heparin 
(70IU/kg) is administered with regular checks of the activated 
clotting time, which is kept around 300 - 350 seconds.
Transseptal puncture and leak crossing
Transseptal puncture is performed using standard techniques 
with a Brockenbrough needle. Puncture can be particularly 
challenging in patients who have undergone multiple surgical 
interventions and who present with a stiff, resistant septum. 
TOE is an elegant tool to guide trans-septal puncture. A short 
axis view of the aortic valve, between 20 and 50 degrees with 
focus on the inter-atrial septum is obtained. A multi-plane 
mode is activated and an orthogonal image, which generally 
corresponds to the bi-caval view, is additionally displayed. Both 
views will allow monitoring of the antero-posterior position 
of the needle (short axis) and judgement of the height of 
the puncture (bi-caval).
Once transseptal, a curved Inoue wire (Toray Medical, Urayasu, 
Japan) can be placed in the left atrium. In general, the left atrium 
is large secondary to chronic mitral regurgitation. Therefore, 
the stiff part of the Inoue wire will be positioned at the level of 
the inter-atrial septum to allow for dilatation with the Inoue 
dilator (Toray Medical, Urayasu, Japan). Dilatation of the septum 
is required to enable crossing of the septum with the 8.5F Agilis 
catheter (St. Jude Medical, St. Paul, MN, U.S.A.). The Agilis 
catheter is a steerable transseptal catheter that enables 
exploration of the peri-mitral valve area in search for the leak. 
Two steerable nobs allow antero-posterior rotation as well as 
curving of the tip of the catheter up to 180 degrees. Occasionally, 
dilatation of the inter-atrial septum (at low pressure with a 
commercially available peripheral balloon) will be required to 
enable crossing of the septum with the Agilis catheter.
Real time 3D TOE, either in zoom mode or in live 3D, is 
particularly useful to guide crossing of the leak as it enables 
instantaneous visualisation of the position and orientation of 
catheters and wires towards the defect. Perception of the 
mitral valve anatomy both on echography and fluoroscopy is 
essential at this stage. Once the Agilis catheter has been 
positioned in the left atrium, a diagnostic coronary catheter 
(mostly a 5F Amplatz Right (AR1)) and a straight 0.035inch 
hydrophilic wire (Terumo Medical, Tokyo, Japan) are advanced 
to the base of the left atrium. Under 3D TOE guidance, the 
MITRAL PARAVALVULAR LEAKS
FIGURE 2:  Quantification of a mitral paravalvular leak.
A:  Calculations of the orifice dimensions using a cutting plane at the level of the prosthetic valve annulus in the grey-scale 3D mode.
B:  Orifice size calculation derived from a similar cutting plane in a 3D colour data set.























Agilis catheter is oriented towards the leak while the AR1 
catheter is just placed with its distal tip outside the Agilis 
catheter. The AR1 is rotated in the direction of the leak, which 
is then crossed antegrade with the hydrophilic wire (Figure 3a). 
With the support of the hydrophilic wire, curved at the apex, 
the AR1 catheter is advanced in the left ventricle. Occasionally 
(and in particularly in “giant” left atria), the AR1 catheter cannot 
be advanced far enough in the left ventricle. In this case, it is 
advised to place a long soft Teflon 260cm 0.035inch exchange 
wire through the AR1 catheter and to exchange for a long 
125cm Multipurpose (MP) catheter. The MP catheter can be 
curved at the apex and left in situ while preparing the closure 
device (Figure 3b). Biplane X-Ray is extremely useful while 
attempting antegrade leak crossing in a lateral and right oblique 
view.
The hydrophilic wire will tend to cross through the prosthesis 
rather than through the leak. Adequate fluoroscopic projections 
will demonstrate if the wire enters the left ventricle outside the 
surgical annulus rather than through the valve. This will further 
be confirmed by 3D TOE while the appearance of ventricular 
ectopic beats also indicates entry into the left ventricle.
Emerging technologies have integrated echocardiography and 
fluoroscopy into a single fusion imaging technique. At present, 
this technology has limited penetration and the authors have 
no experience with it.
Device preparation, deployment and testing
The choice of the device that will be deployed is the result of a 
consensus between the echocardiographist and the inter-
ventional cardiologist. It takes into account the position, size 
and aspect of the leak. Upfront, the choice diverges between 
the number of anticipated devices needed and the type of 
device. Narrow (less than 3mm in diameter) but potentially 
long crescent leaks are mostly treated with one or more 
Amplatzer vascular plug III devices (AVP III, St. Jude Medical, 
St. Paul, MN, U.S.A.) while larger leaks (>3mm) mostly require 
one or more Amplatzer muscular VSD devices (St. Jude 
Medical, St. Paul, MN, U.S.A.). Very large leaks may be judged 
upfront not feasible or requiring multiple muscular VSD devices 
that may require a second transseptal puncture in order to 
enable simultaneous release of 2 devices.
The closure devices are chosen 2mm to 3mm larger than the 
diameter of the defect. They are flushed and prepared with a 
French compatible TorqVue (St. Jude Medical, St. Paul, MN, 
U.S.A.) transseptal delivery catheter. Of note, the longest 
TorqVue I catheter is only 80cm long and may be too short to 
cross the leak, in particular in tall patients or giant left atria. A 
120cm TorqVue II catheter can then be used. The TorqVue II 
is not used upfront as it implies opening an additional package 
and requires particular manipulation of the implant loader, 
which is shorter than the TorqVue II catheter.
If crossing of the leak with a TorqVue I is judged feasible and 
the closure device has been loaded within the delivery sheath, 
a 260cm 0.035inch long Amplatzer super stiff wire (Boston 
Scientific, Natick, MA, U.S.A.), manually widely curved at its tip, 
is advanced across the diagnostic coronary catheter. This wire 
is engaged in a stable position at the apex of the left ventricle. 
It is advised to perform this only at this stage, as this wire will 
tend to retract towards the left atrium over time.
The Agilis and diagnostic coronary catheter are withdrawn 
while leaving the super stiff wire in place. The TorqVue I 
catheter is then advanced over the stiff wire through the inter-
atrial septum and the leak into the left ventricle. Subsequently, 
the dilator and wire are withdrawn and the loader with the 
closure device is screwed on the TorqVue I catheter, as for any 
typical defect closure procedure using Amplatzer technology. 
The closure device is pushed up to the tip of the TorqVue 
catheter. Further advancement allows opening up of the distal 
part of the closure device, often accompanied by gently pulling 
back the TorqVue catheter to avoid entrapment of the 
device into trabeculae or the mitral subvalvular apparatus. The 
TorqVue closure device is than pulled back under fluoroscopic 
echo guidance leaving the proximal-central part of the closure 
device partially deployed (Figure 3c). At the level of the annulus, 
this part of the device may be further deployed while holding 
firm traction on the device. Once well apposed on the 
ventricular side, the prosthesis is inspected by echocardiography 
for potential interference with the valve leaflets. Subsequently, 
the proximal-atrial part of the implant will be released by 
withdrawal of the TorqVue sheath while keeping the implant in 
a stable position (Figure 3d). Correct placement can be judged 
by biplane X-Ray and 3D TOE. Echocardiography will further 
confirm this and enable quantification of any residual leak. 
Deployment is quite similar whether a plug III or muscular VSD 
device is used. As mentioned before, the latter will be implanted 
in large leaks.  If multiple muscular VSD implants are considered, 
a second transseptal puncture and device placement to allow 
simultaneous release may be required in order to anticipate 
device embolisation. Incomplete closure of large leaks by 
muscular VSD devices carries a risk of massive post procedural 
hemolysis, which will compromise final procedural success. 
Therefore, the objective should be complete or near complete 
closure by the techniques described above. Figures 3 and 4 
demonstrate the different steps from leak crossing to deploy-
ment of a muscular VSD device in a patient with a large 
paravalvular leak, respectively from a fluoroscopic and 3D TOE 
perspective. Figures 5 and 6 demonstrate full closure of this 






FIGURE 3:  Steps in paravalvular leak closure, fluoroscopic perspective.
A:  Crossing of a large postero-lateral leak by means of a hydrophilic wire (thick arrow at the level of the leak) and an Amplatz Right coronary 
catheter (dotted arrow) through an Agilis catheter (thin arrow), LA denotes left atrium, LV is left ventricle.
B: Positioning of a 125cm long 6F multipurpose catheter across the leak at the apex of the left ventricle.
C:  Deployment of the distal part of a muscular Ventricular Septum Closure device (VSD) in the left ventricle. The arrow demonstrates clearly 
that the central part of the implant is only partially deployed.
D:  Anchoring of the VSD device within the leak. The full-line arrow indicates the distal (ventricular) part of the implant, while the dotted arrow 





















FIGURE 4:  Steps in paravalvular leak closure, echographic perspective.
A:  3D echo visualisation of an Agilis catheter across the inter-atrial septum (dotted arrow) and positing of a diagnostic coronary catheter (full-
line arrow) through the leak.
B: 2D orthogonal multi-plane views demonstrating the deployment of the distal (ventricular) part (arrow) of a VSD device. 
C: Assessment of a deployed VSD (arrow) implant device prior to release.
D: Assessment after implantation of 2 VSD devices.
The vascular plug III is particularly suited for slit-like leaks. 
Antegrade crossing of these leaks will be more time consuming 
whether it be with the hydrophilic wire or delivery catheter. A 
TorqVue II catheter will be more convenient in this case. The 
Agilis catheter can be left in place and provides additional back 
up to cross the leak while this delivery catheter can host the 
largest plug available. If indicated, a second serial plug can be 
implanted safely without the need for a second transseptal 
puncture, as device embolisation is very unlikely. Small residual 
leaks will be more forgiving in terms of haemolytic risk. It is 
speculated that this is due to the softer consistency of the 
device.
Devices are released upon gently clockwise counter rotation 
and after gentle wiggling manoeuvres to check for device 
stability. In general, the transseptal catheter and delivery cable 
are not co-axial to the plug, which will often slightly rotate to its 
final position upon release.
At the end of the procedure, it is important to screen for 
potential complications. The presence of pericardial effusion, 
the integrity of the inter-atrial septum, potential displacement 
of the closing device and adequate functioning of the valve 
prosthesis are verified. 
Anticipation of complications
The most feared complication of paravalvular leak closure is 
device embolisation. The risk for this complication can be kept 
minimal by adequate sizing of the leak by 3D TOE and defining 
the interventional strategy upfront.
Another more frequent complication is total or partial leaflet 
blockage of mechanical prostheses. This may be corrected by 
gently pulling back the implant into the channel of the leak, 
device recapture and repositioning or downsizing of the 
implant. This complication occurs more often with the muscular 
VSD device because of its inherent properties and alternatively 
an Amplatzer PDA may be considered in specific cases. Even if 
device repositioning is technically feasible, it is advised to assure 
a stable position before release, as the implant may slide back 
to its original position once released, thereby blocking a leaflet. 
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A stable position can be assessed by gentle wiggle manoeuvres 
and morphological analysis of the atrial side of the device by 3D 
TOE. Pre-operative 3D TOE imaging will demonstrate the 
distance of the leak to the surgical annulus, the leaflet structures 
and position of the leak towards the plane of the valve. 
Integration of this information into the interventional strategy 
should minimise the risk of leaflet blockage.
Worsening or appearance of haemolytic anemia is another 
feared complication after paravalvular leak closure. It may be 
encountered after implantation of the more rigid muscular VSD 






FIGURE 6:  Steps in paravalvular leak closure, deploy-
ment of additional devices, echographic views.
A: Final image after implantation of a third device.
B:  3D colour flow analysis of the paravalvular reflow jet before 
intervention.
C:  Final colour flow assessment after implantation of 3 VSD 
devices.
FIGURE 5:  Steps in paravalvular leak closure, 
deployment of additional devices, fluoroscopic views.
A:  Positioning of a second VSD device just prior to release.



















From a theoretical perspective, closure of paravalvular leaks in 
bioprostheses is easier as the risk of interference with the 
leaflets is much lower than with mechanical valves. There is 
theoretical risk of eroding the bioprosthesis by a too large 
implant but this complication has, at present, not been 
described.
Literature overview
A limited number of papers have been published on para-
valvular leak closure. In total less than 200 patients have been 
reported, in a few series of papers, with the largest experiences 
being from the Mayo Clinic and Lennox Hill Heart Institute in 
the U.S. Reported acute procedural success ranged between 
70 and 80%. The above-mentioned complications have all 
been reported, all in single digit numbers. Recently, a dedicated 
device has been developed by Occlutech (Helsenborn, 
Sweden) and has received the CE mark. It has been implanted 
in a small number of patients by hybrid surgical-percutaneous 
transapical approach (personal communication, unpublished 
data). This device has a square or rectangular design and is 
available in different sizes. At present, there is no data available 
on antegrade closure with this new implant.
CONCLUSIONS
Percutaneous closure is emerging as the technique of choice for 
paravalvular leakage. 3D TOE provides insight in the mecha-
nisms, morphology and feasibility of percutaneous closure. If 
judged technically feasible, the procedure should be guided by 
3D TOE using available, non-dedicated closure implants. This 
intervention has the potential to palliate patients excluded from 
any other therapeutic alternative.
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